Pages 741-748 (doi:10.741) Axitinib for renal cell carcinomaGuru Sonpavde_1 MD, Thomas E Hutson2 DO PharmD FACP +1 216 636 1937; Author for correspondence_ _Background_: The approval of sunitinib, sorafenib and temsirolimus has dramatically altered the management of renal cell carcinoma (RCC).IFN may also be added to the therapeutic armamentarium.(AG-013736) is an oral and selective tyrosine kinase inhibitor.Data supporting the development of axitinib for RCC are reviewed.Preclinical and clinical data available for axitinib for RCC are presented.Axitinib inhibits VEGFR-1, VEGFR-2 and VEGFR-3 with polar potencies, and PDGFR-, PDGFR- and c-kit with nanomolar potencies.II clinical trials of axitinib in pretreated RCC following sorafenib or cytokine treatment have demonstrated promising activity apanied by a favorable toxicity profile.Read more Exogenous subclinical hyperthyroidism impairs endothelial function in nodular goiter patients
Get more American society for dermatologic surgery supports current labeling of allergan's botox(r) products
